Our results show that cabozantinb plus telaglenastat synergized to inhibit RCC cell proliferation in vitro and combined effectively to reduce both glucose and glutamine consumption, lower OCR, and suppress signal transduction pathways downstream of VEGFR, MET and AXL [59]. Here, AXL is linked to renal cell carcinoma.